Atossa Therapeutics Reports Positive Phase 2 Trial Results
Atossa Therapeutics, Inc. (NASDAQ:ATOS), a promising clinical-stage biopharmaceutical company, is making waves in the fight against breast cancer. Their recent announcement revealed encouraging preliminary results from a phase 2 trial for their innovative breast cancer drug, (Z)-endoxifen. This trial, part of the I-SPY 2 Endocrine Optimization Pilot (EOP), demonstrated that a low dose of the drug achieved significant efficacy, with an impressive 95% of patients receiving over 75% of the planned treatment.
Understanding the Trial Details
The trial engaged 20 women diagnosed with estrogen receptor-positive (ER+)/HER2-negative breast cancer, with the treatment period running from early 2023 through mid-2024. The results from this study were remarkable: just 10 mg of (Z)-endoxifen taken orally once daily led to a substantial decrease in key disease biomarkers. Notably, after just three weeks of treatment, the harmful protein Ki-67, indicative of cancer cell growth, was reduced by 69% from the baseline levels. Additionally, the functional tumor volume (FTV) saw a reduction of 30.4%, raising hopes that (Z)-endoxifen could help slow the progression of this aggressive form of breast cancer.
Patient Experience and Side Effects
During the trial, participants reported only mild side effects, including hot flashes, insomnia, and fatigue. Remarkably, there were no reports of dose reductions or discontinuation of treatment due to adverse effects. Moving forward, Atossa Therapeutics plans to conduct further assessment, including surgical Ki-67 values and imaging after 24 weeks of treatment.
CEO's Insights on the Trial
Dr. Steven Quay, the CEO of Atossa Therapeutics, expressed his excitement regarding the swift reduction in Ki-67 and FTV, signifying progress in the pursuit of effective treatments for breast cancer. The company is also exploring the potential of higher doses of (Z)-endoxifen in conjunction with other medications to amplify treatment effectiveness.
The Trial’s Broader Implications
The I-SPY 2 EOP trial primarily focuses on patients identified with newly diagnosed ER+ invasive breast cancer who may not gain advantages from chemotherapy. The exciting findings from this trial will be discussed in detail at the forthcoming RISE UP Breast Cancer Conference, capturing the attention of the medical community.
Mechanism and Advantages of (Z)-endoxifen
(Z)-endoxifen operates as a powerful Selective Estrogen Receptor Modulator (SERM), selectively inhibiting estrogen receptors while simultaneously targeting the oncogenic protein PKC?1. This unique approach is particularly beneficial for patients who have shown resistance to traditional hormonal treatments, offering promising alternatives with lesser side effects compared to established treatments like tamoxifen.
Atossa's Ongoing Developments
Atossa's proprietary oral formulation of (Z)-endoxifen is specifically designed to enhance drug stability and effectiveness, avoiding degradation in the acidic environment of the stomach. This exciting drug is currently undergoing evaluations in five different phase 2 clinical trials, investigating various breast cancer conditions and further validating its potential.
Regulatory Support and Recent Initiatives
In recent developments, Atossa Therapeutics has voiced approval for updated FDA mammography guidelines that require facilities to notify patients about breast density, a crucial factor influencing breast cancer risk. Atossa is actively committed to advancing the capabilities of breast cancer treatments and projects, including their innovative (Z)-endoxifen therapy, and has taken strides in the SMART study—a phase 2 trial utilizing artificial intelligence to assess breast cancer risks more accurately.
Strengthening Intellectual Property
Additionally, at the forefront of pharmaceutical innovation, Atossa has recently obtained a new patent from the USPTO for compositions containing endoxifen. This patent boosts Atossa’s intellectual property portfolio, granting enhanced protection for their endoxifen formulations and their methods of delivery.
Market Position and Projections
The present market capitalization of Atossa Therapeutics stands at around $177.32 million, reflecting a valuation as investors take note of the company's robust drug pipeline, including the promising results of (Z)-endoxifen. Despite not being profitable over the last twelve months, Atossa has experienced a remarkable price total return of approximately 110.32%. Such promising outcomes have likely piqued investor interest and optimism regarding the company’s future.
Collaborations and Future Trials
Atossa is also collaborating with Quantum Leap Healthcare Collaborative to initiate several clinical trials focused on breast cancer therapies. A noteworthy trial is looking into the combination of Atossa's (Z)-endoxifen and Eli Lilly's abemaciclib for high-risk women newly diagnosed with ER+/HER2- breast cancer. Anticipated results from these trials could substiate the safety and efficacy of (Z)-endoxifen further, creating a more substantial framework for treatment options.
Frequently Asked Questions
What is (Z)-endoxifen?
(Z)-endoxifen is a Selective Estrogen Receptor Modulator (SERM) being researched for the treatment of ER+ breast cancer, with promising results in recent trials.
When were the trial results announced?
The preliminary positive results from the phase 2 trial of (Z)-endoxifen were recently announced by Atossa Therapeutics.
What are the main findings of the trial?
The trial found that (Z)-endoxifen significantly reduced key biomarkers related to breast cancer, showing a drop in the Ki-67 protein and tumor volume.
What are the next steps for Atossa Therapeutics?
Atossa plans to continue its evaluation of (Z)-endoxifen in additional trials and investigate combinations with other therapies to improve treatment outcomes.
How is Atossa's financial status?
Atossa currently has a market capitalization of around $177.32 million and has maintained a strong liquidity position, holding more cash than debt.
